XFOR

X4 Pharmaceuticals, Inc. (XFOR) | Rumor.io

X4 Pharmaceuticals

XFOR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,695

Bullish sentiment (50-day avg)82%

Price to earnings ratio2.07

Market capitalization298.9M

Earnings per share1.43

Dividend yield (TTM)—

Revenue (annual)35.1M

Net income (annual)-79.2M

Social

What share of all stock conversation is about XFOR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jul 23

XFOR Pharmaceuticals, Inc. has seen a significant increase in stock price, up 13.55% to $3.695.
The company's stock appears to be in a "pump" phase, with many users expressing enthusiasm and encouraging others to hold onto their shares.
The stock's price increase has led to a surge in diamond hands, with many users celebrating the stock's rise and predicting further gains.

Generated by AI

Sentiment

Of the messages about XFOR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	60% -40	85.55% +9.32
Bearish	—	0%	40% new	14.45% -9.32

Bullish· Jul 23

The price of XFOR has increased by 13.55%, reaching $3.695, and the community is urging others to hold on for further gains.
The shorts are running and diamond hands are grinning, with many posts expressing confidence in the company's ability to squeeze out further gains.
The community is in a state of "YOLO mode", with many investors having secured their bags and looking forward to the next moon, and are urging others to join them in holding on for further gains.

Bearish· Aug 13

The company's recent $40M share offering at $1.40 may have locked in a massive discount for PIPE investors, drawing criticism and selling pressure.
The financing itself may be a heavy weight on the stock, especially considering the deep discount from the pre-halt price of $2.60.
The company's massive warrants issuance at $1.42 may further exacerbate the selling pressure, as insiders may be selling their shares to exercise these warrants.

Generated by AI

Topics

Of the messages about XFOR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	67.61%
Analysts	—	0%	0%	7.39%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	25%

Announcements· Sep 17

X4 Pharmaceuticals, Inc. ($XFOR) announced a 50% workforce reduction, resulting in annualized cost savings of approximately $13M, with a one-time cost of $3.3M for severance and employee termination-related costs.
The restructuring plan includes the appointment of John Volpone as Chief Operating Officer (COO) and Dr. Adam Craig as Executive Chairman, overseeing clinical development, while Dr. Christophe Arbet-Engels, Chief Medical Officer, resigns for personal reasons.
The company estimates that the restructuring will extend its cash runway and enable it to focus on completing the Phase 3 4WARD trial in chronic neutropenia, a key development program.

Technical Analysis· Aug 13

X4 Pharmaceuticals, Inc. (XFOR) has seen a 93.38% increase in price from $1.51 to $3.12, with strong momentum following an $85 million offering.
A break above $3.32 could open the door for further gains in XFOR, but the stock is currently facing resistance at $3.08 and $3.15.
XFOR is in a consolidation phase underneath the VWAP, building positions for a potential break through and rally higher, with bulls needing to break $3.50 to run the stock to its previous highs.

Generated by AI

Community

Of the messages about XFOR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	40.89%
Newcomers	—	0%	0%	59.11%

Regulars· Aug 22

XFOR is trading at $3.18 with 8K shares exchanged, and technical points are set at $3.50, $4.13, and $5.09, while the stop-loss is at $2.93.
Some regulars are concerned about the potential for a short squeeze due to the high short interest in XFOR, citing a 44.8% short interest ratio and a 21.6% short volume ratio.
The company's stock price has been impacted by the recent FDA rejection of its NDA for XFOR-225, with some analysts downgrading their target prices for the stock.

Newcomers· Jul 23

The newcomers are focused on the significant price increase of XFOR, with the stock price rising by 13.55% to $3.695.
The focus is on the idea of holding onto (HODL) the stock as it continues to rise, with some users mentioning the potential for a "squeeze" or a "moon".
The posts are centered around the idea of being a "diamond hand", someone who holds onto their stock through price fluctuations, and the potential for a "pump train" or a significant price increase.

Generated by AI

X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

5d agoYahoo Finance

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

18d agoYahoo Finance

X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook

19d agoInvesting.com

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmac

21d agoYahoo Finance

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the positive outcome of its Type C Meeting with the U.S. Food and Drug Administration (FDA) related to the global 4WARD Phase 3 clinical trial. The pu

22d agoYahoo Finance

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28d agofinance.yahoo.com

Also Discussed

Investors talking about XFOR also mention

#	Name	Attention
1	DAWN - Day One Biopharmaceuticals, Inc.	——
2	EFTR - eFFECTOR Therapeutics, Inc.	——
3	TG Therapeutics Inc.TGTX	0.01%+0
4	Rocket Pharmaceuticals, Inc.RCKT	0%+0
5	VCI Global Ltd.VCIG	0%0
6	PDS Biotechnology CorporationPDSB	0%-0.01
7	Seres Therapeutics Inc.MCRB	0%0
8	Aquestive Therapeutics Inc.AQST	0%+0
9	EQRX - EQRx, Inc.	——
10	Ardelyx IncARDX	0.01%+0.01

X4 Pharmaceuticals, Inc.

Healthcare
Biotechnology

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders. The company’s core work centers on CXCR4-targeted medicines, including mavorixafor, an oral small-molecule antagonist designed to improve immune cell trafficking and address conditions marked by chronic neutropenia and immunodeficiency. X4 Pharmaceuticals markets XOLREMDI in the United States and continues to evaluate mavorixafor in additional indications through clinical development programs. Its portfolio and commercial activity place it at the intersection of immunology, hematology, and rare-disease care, serving patients with significant unmet medical needs. Based in Boston, Massachusetts, X4 Pharmaceuticals plays a specialized role in the biotechnology market by focusing on treatments for underserved patient populations.

Website

Location

61 North Beacon Street

Boston, MA, 02134

United States

Social

What share of all stock conversation is about XFOR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jul 23

XFOR Pharmaceuticals, Inc. has seen a significant increase in stock price, up 13.55% to $3.695.
The company's stock appears to be in a "pump" phase, with many users expressing enthusiasm and encouraging others to hold onto their shares.
The stock's price increase has led to a surge in diamond hands, with many users celebrating the stock's rise and predicting further gains.

Generated by AI

Sentiment

Of the messages about XFOR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	60% -40	85.55% +9.32
Bearish	—	0%	40% new	14.45% -9.32

Bullish· Jul 23

The price of XFOR has increased by 13.55%, reaching $3.695, and the community is urging others to hold on for further gains.
The shorts are running and diamond hands are grinning, with many posts expressing confidence in the company's ability to squeeze out further gains.
The community is in a state of "YOLO mode", with many investors having secured their bags and looking forward to the next moon, and are urging others to join them in holding on for further gains.

Bearish· Aug 13

The company's recent $40M share offering at $1.40 may have locked in a massive discount for PIPE investors, drawing criticism and selling pressure.
The financing itself may be a heavy weight on the stock, especially considering the deep discount from the pre-halt price of $2.60.
The company's massive warrants issuance at $1.42 may further exacerbate the selling pressure, as insiders may be selling their shares to exercise these warrants.

Generated by AI

Topics

Of the messages about XFOR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	67.61%
Analysts	—	0%	0%	7.39%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	25%

Announcements· Sep 17

X4 Pharmaceuticals, Inc. ($XFOR) announced a 50% workforce reduction, resulting in annualized cost savings of approximately $13M, with a one-time cost of $3.3M for severance and employee termination-related costs.
The restructuring plan includes the appointment of John Volpone as Chief Operating Officer (COO) and Dr. Adam Craig as Executive Chairman, overseeing clinical development, while Dr. Christophe Arbet-Engels, Chief Medical Officer, resigns for personal reasons.
The company estimates that the restructuring will extend its cash runway and enable it to focus on completing the Phase 3 4WARD trial in chronic neutropenia, a key development program.

Technical Analysis· Aug 13

X4 Pharmaceuticals, Inc. (XFOR) has seen a 93.38% increase in price from $1.51 to $3.12, with strong momentum following an $85 million offering.
A break above $3.32 could open the door for further gains in XFOR, but the stock is currently facing resistance at $3.08 and $3.15.
XFOR is in a consolidation phase underneath the VWAP, building positions for a potential break through and rally higher, with bulls needing to break $3.50 to run the stock to its previous highs.

Generated by AI

Community

Of the messages about XFOR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	40.89%
Newcomers	—	0%	0%	59.11%

Regulars· Aug 22

XFOR is trading at $3.18 with 8K shares exchanged, and technical points are set at $3.50, $4.13, and $5.09, while the stop-loss is at $2.93.
Some regulars are concerned about the potential for a short squeeze due to the high short interest in XFOR, citing a 44.8% short interest ratio and a 21.6% short volume ratio.
The company's stock price has been impacted by the recent FDA rejection of its NDA for XFOR-225, with some analysts downgrading their target prices for the stock.

Newcomers· Jul 23

The newcomers are focused on the significant price increase of XFOR, with the stock price rising by 13.55% to $3.695.
The focus is on the idea of holding onto (HODL) the stock as it continues to rise, with some users mentioning the potential for a "squeeze" or a "moon".
The posts are centered around the idea of being a "diamond hand", someone who holds onto their stock through price fluctuations, and the potential for a "pump train" or a significant price increase.

Generated by AI

X4 Pharmaceuticals

Social

Jul 23

Bullish· Jul 23

Bearish· Aug 13

Announcements· Sep 17

Technical Analysis· Aug 13

Regulars· Aug 22

Newcomers· Jul 23

Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

X4 Pharmaceuticals, Inc.

Company Information

Location

Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Social

Jul 23

Bullish· Jul 23

Bearish· Aug 13

Announcements· Sep 17

Technical Analysis· Aug 13

Regulars· Aug 22

Newcomers· Jul 23